Kymera Therapeutics, Inc.
KYMR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $5 | $4 | $2 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $5 | $3 | $2 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -75.9% | -48.1% | 198.9% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -2,580.7% | 81.8% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,870% | -648.5% | -287.2% | -929.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,973% | -667.6% | -296.7% | -956.9% |
| EPS Diluted | -0.94 | -0.95 | -0.82 | -0.88 |
| % Growth | 1.1% | -15.9% | 6.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |